CLOs on the Move

National Quality Forum

www.qualityforum.org

 
The National Quality Forum (NQF) is the nation`s resource for healthcare quality measurement and improvement. NQF is an independent, not-for-profit, membership-based organization that brings healthcare stakeholders together to recommend quality measures and improvement strategies that reduce costs and help patients get better care. NQF`s membership consists of more than 400 organizations that represent physicians, nurses, hospitals, healthcare systems, patients, families, health plans, employers, and others committed to healthcare quality. Through its multistakeholder membership, NQF facilitates an open and thorough dialogue on healthcare measurement and improvement, and leads national collaboration to improve health and healthcare quality for all Americans.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Amol Batra
 General Counsel Profile

Similar Companies

MBF Healthcare Partners

MBF Healthcare Partners is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HandsFree Health

WellBe® is a digital health platform that provides voice-activated assistance with health questions, reminders, and entertainment using a smart speaker.

Cross Tree Capital

Cross Tree Capital is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AbboMax

AbboMax is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.